Navigation Links
ORTHO Sera ID-MTS Antigen Phenotyping Cleared on ORTHO VISION® Platforms in United States and Canada

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing format used for blood phenotyping for patients in need of transfusion, is cleared to run on ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. The clearances allow testing for more than 99 percent of the most commonly tested blood group antigens to be performed on one platform, driving greater value and efficiency.

The suite was cleared by the U.S. Food and Drug Administration for use on the ORTHO VISION® Analyzer in October 2019, and for use on the ORTHO VISION® Max in January 2020. The suite received Health Canada approval in January 2020.

Watch a video on how Sera works:

“Ortho Clinical Diagnostics is proud to offer our laboratory partners solutions that help them quickly test donor blood for the most-needed phenotypes and confidently provide it to patients in need of transfusion,” said Bob Stowers, head of Ortho's transfusion medicine product portfolio. “With the ability to analyze the most commonly tested antigens on a single ORTHO VISION system and results in under 25 minutes, lab teams are better equipped to help clinicians focus on what matters most—treating their patients.”

During pre-transfusion testing, lab professionals routinely encounter complex patient samples that require extended antigen typing. These patients have developed atypical antibodies to blood group antigens and require additional testing to find compatible blood.

Its antisera additive approach means customers always have the appropriate reagents available and allows extended phenotyping to be personalized according to patient needs—reducing waste and enhancing efficiency.

With end-to-end full automation on the ORTHO VISION and ORTHO VISION Max analyzers, ORTHO Sera minimizes the potential for human error—improving safety—and provides consistent, reliable results while freeing up lab professionals to focus on value-added tasks.

The 13 ORTHO Sera reagents available in the U.S. and Canada on the ORTHO VISION Analyzer and ORTHO VISION Max include Anti-D (DVI), Anti-D (IAT), Anti-Fya, Anti-Fyb, Anti-Jka, Anti-Jkb, Anti-K, Anti-Lea, Anti-Leb, Anti-N, Anti-P1, Anti-S, Anti-s.

For more information, visit

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, serves the clinical laboratory and immunohematology communities.

Ortho’s high-quality products and services help hospitals, hospital networks, blood banks and labs in more than 125 countries and territories deliver consistently fast, accurate, and reliable results that allow clinicians to make better-informed treatment decisions.

Ortho’s lab solutions provide sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories to help them run more efficiently and effectively and improve patient care.

Ortho’s blood typing products help ensure every patient receives blood that is safe, the right type and the right unit.

Why does Ortho continue to innovate and provide industry-changing solutions? Because every test is a life.

For more information about Ortho’s solutions and services, visit, or visit Ortho on social media: LinkedIn, Twitter, Facebook, Instagram and YouTube.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology technology :

1. VGI Medical Engages Ortho Spine Partners (OSP) to Lead US Commercialization Efforts
2. Independent Orthodontic Practices to Gain Access to Advanced Data Solutions
3. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, will present a clinical abstract on Allogeneic Adipose Stem Cell Bio-Distribution at the Veterinary Orthopedic
4. Ortho Clinical Diagnostics Recognized with Two Global Business Excellence Awards
5. Brian Mehling, M.D., US orthopedic trauma surgeon, stem cell researcher, founder of Blue Horizon International to attend World Economic Forum in Davos
6. New Orthopedic Device Technology Moves From Lab Toward Operating Room With Help From Philadelphia-Based Start-Up OrthoMend Research, Inc.
7. Orthogonal Congratulates Nanowear on the FDA Clearance of their Flagship Product, SimplECG™.
8. Orthopedic Surgeon Speaks On Using Medicrea’s Patient-Specific UNiD Rods To Treat Scoliosis
9. Global Orthobiologics Market Outlook 2020 - Research and Markets
10. Smarter Alloys Announces Commercial Launch of SmartArch Orthodontic Archwire
11. In’Tech Medical Expands in Asia with the Acquisition of Ortho Solutions
Post Your Comments:
(Date:5/26/2020)... PARK, Calif. (PRWEB) , ... May 26, 2020 , ... ... , the most recognized brand of smart garage door openers, announce a new integration ... line of Wi-Fi enabled garage door openers powered by Aladdin Connect® can now be ...
(Date:5/15/2020)... ... May 14, 2020 , ... ... working cell banks and hMSC bioprocess systems, today announced the launch of ... hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC is the only system designed with hMSC-EV ...
(Date:5/14/2020)... ... May 12, 2020 , ... NanoString Technologies , ... thousands of industry leaders, clinicians, research scientists, medical professionals and academics from around ... MD, Director of the Center for Cellular Immunotherapies at the Perelman School of ...
(Date:5/5/2020)... , ... May 05, 2020 , ... ProductLife Group ... high-profile CEO. Xavier Duburcq joins the group after 13 years at Altran, where he ... Holding a PhD in Immunology and being a Pharmacist, Xavier was involved in his ...
Breaking Biology Technology:
(Date:5/15/2020)... ... May 15, 2020 , ... The National Institutes of Health (NIH) ... based in Frederick, Maryland and Tysons Corner, Virginia, to provide patent legal services under ... another in the field of chemistry. The firm is one of nine firms in ...
(Date:5/6/2020)... Md. and LEXINGTON, Mass. (PRWEB) , ... May 06, 2020 , ... ... Hemanext Inc. , a privately held medical technology company dedicated to improving the quality, ... announce a new partnership that will help SCDAA deliver on its mission and meet ...
(Date:5/1/2020)... ... May 01, 2020 , ... More than 600 people undergo ... High-Risk Cancer Program, which is led by two genetic counselors. , My Gene ... it is teaming up with UConn’s High Rick Program to ensure that UConn’s patients ...
Breaking Biology News(10 mins):